Enzymes for Research, Diagnostic and Industrial Use
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Fructosyl Amine-Oxygen Oxidoreductase (FAOX) is an enzyme of great biological significance. The general term comprises a group of proteins capable of reverting protein glycation, a specific posttranslational modification that occurs particularly under hyperglycemic conditions. It is part of the wider enzyme classification of oxidoreductases and the subclass amine-oxygen oxidoreductases. This enzyme is of particular interest due to its role in glycation, reversing processes that can lead to chronic diseases such as diabetes.
The characteristic structure of FAOX spans across molecular, secondary, tertiary, and quaternary levels, emphasizing its impressive architectural intricacy. These structural levels contribute heavily to the function and efficiency of FAOX. The three-dimensional design of its active site is particularly remarkable, highlighting its specificity for its substrate.
As an Oxidoreductase, the enzyme's primary function is to catalyze the oxidation-reduction process. Predominantly, it catalyzes reactions that involve the conversion of fructosyl molecules back into their original amine, liberating fructose in the process. This gives it a key role in glycation reversal, which initiates glucose tolerance. The enzyme prevents the permanent formation of advanced glycation end-products (AGEs), a key characteristic in metabolic and aging related diseases.
FAOX essentially operates by redirecting the process of Amadori rearrangement in protein glycation. It engages its flavin adenine dinucleotide cofactor to abstract a hydride ion from the substrate. It subsequently carries out electron transfer to molecular oxygen, converting it to hydrogen peroxide. This role as a hydride transfer catalyst is central to the 'de-glycating' mechanism of FAOX.
The therapeutic potential of FAOX lies mainly in diseases influenced by advanced glycation end-products (AGEs). Its intervention in the formation of AGEs presents a potential therapeutic approach for related chronic diseases like diabetes and Alzheimer’s. Its utility extends to biomarker research where the expression and activity of the enzyme could indicate disease progress.
In a clinical setting, the role of FAOX in diabetes has been markedly recognized. AGEs, a harmful product of hyperglycemia, can be mitigated by FAOX activity, hence controlling the diabetic condition. In addition, the links between AGEs and neurodegenerative diseases highlight the possible role of FAOX in combating conditions such as Alzheimer's. Elevated levels of this enzyme could serve as an indicator of disease, thus potentially useful for diagnosis.
In addition to its role in the catabolism of fructosyl-amines, Fructosyl Amine-Oxygen Oxidoreductase has garnered significant attention due to its potential applications in various fields. The enzyme's ability to detoxify and degrade AGEs has implications for the development of therapeutic interventions for diabetic complications and other AGE-related diseases. Furthermore, the unique catalytic properties of Fructosyl Amine-Oxygen Oxidoreductase have attracted interest in biocatalysis and biotechnology, where the enzyme may be utilized for the synthesis of valuable ketoamines and for the enzymatic oxidation of other substrates.
To conclude, Fructosyl Amine-Oxygen Oxidoreductase is an enzyme with multifaceted significance. Its role in the intricacies of glycation and its subsequent reversal present prospects for biomarker research and therapeutic development against chronic diseases such as diabetes and Alzheimer's. However, the knowledge of this enzyme, its mechanism, and its clinical significance is still in its nascent stage and requires further research for comprehensive understanding and utilization.